Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Gene therapy cut need for blood transfusions in beta thalassemia

Marktel S et al. ASH 2017 Abstract 355

Key clinical point: Gene therapy engraftment was achieved sooner using intrabone delivery.

Major finding: After a median of 16 months of follow-up, five of seven patients who received this novel gene therapy needed markedly fewer blood transfusions than at baseline.

Data source: An interventional phase 1/2 trial of seven patients with transfusion-dependent beta thalassemia.

Disclosures: Telethon Foundation provided funding. Dr. Marktel disclosed research funding from GlaxoSmithKline, which has licensed the therapy.

Source: Marktel S et al. ASH 2017 Abstract 355.

Read the full article.

Citation:

Marktel S et al. ASH 2017 Abstract 355

This Week's Must Reads

Observational study shows hydroxyurea well tolerated in sickle cell disease, Dauvergne B et al. FSCDR 2018, presentation JSCDH-D-18-00052

Large cohort study demonstrates DOAC safety vs. warfarin , Vinogradova Y et al. BMJ 2018;362:k2505.

Oral administration of arsenic + ATRA effective for APML, Zhu HH et al. Lancet Oncol. 2018;19:871-9.

Must Reads in Bleeding Disorders

Thrombocytopenia in pregnancy raises risk of complications, Reese J et al. N Engl J Med. 2018;379:32-43.

Red cell tranfusion may increase risk of postsurgical VTE, Goel R et al. JAMA Surg. 2018 Jun 13. doi: 10.1001/jamasurg.2018.1565

Dapagliflozin suppresses hepcidin, boosts hematocrit, Ghanim HA et al. AACE 2018, Abstract 228.

In hemophilia A, reduced frequency prophylaxis was safe, cut costs, Feldman BM et al. Lancet Haematol. 2018 May 3. doi: 10.1016/S2352-3026(18)30048-6.

Reducing morbidity in postpartum hemorrhage, Smith R et al. Annual clinical and scientific meeting of the American Society of Obstetricians and Gynecologists 2018, Abstract 26R.